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Abstract To investigate the regulatory mechanisms of human 
angiotensinogen (ANG) gene expression in the brain, we 
analyzed the 1.3-kb promoter by transfection studies and gel 
shift assays. The region from —106 to +44 was sufficient for 
promoter activity in glioblastoma cells, and multiple nuclear 
factors including AGCF2 (human ANG core promoter binding 
factor 2) bound within this 150-bp region. The mutations within 
AGCF2-binding elements decreased the transcriptional activity 
in glioblastoma cells but rather increased it in hepatoma cells. 
These results indicate that AGCF2 has a differential function 
between these cells and contributes to the glia-dependent 
angiotensinogen promoter activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Angiotensinogen (ANG), the unique substrate of renin in 
the renin-angiotensin system (RAS), is the precursor of the 
octapeptide hormone, angiotensin II (All), which plays an 
important role in the regulation of blood pressure and electro-
lyte homeostasis [1,2]. Until recently, All was believed to be 
exclusively a circulating hormone, but since components of 
the RAS have been demonstrated in a variety of tissues, 
such as adrenal glands, kidney, heart, and also in the brain, 
the various tissue RAS is considered to play a role in local 
tissue regulation [3,4]. 
It is well established that the injection of All into the brain 
causes significant physiological responses, including increases 
in blood pressure, drinking behavior, and vasopressin release 
[5-8]. In addition to these effects, several lines of evidence 
have suggested that All exerts specific actions according to 
the developmental changes in relative expression of the recep-
tor subtypes in the brain [9-11]. Recently, Ichiki et al. [12] and 
Hein et al. [13] reported that mice lacking AT2 receptor have 
an impaired drinking response to water deprivation as well as 
a reduction in spontaneous movement. These results support 
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the notion that the brain RAS plays an important role inde-
pendently of circulating one. 
ANG is one of the important regulators in the brain RAS, 
because there is a 28% greater expression of the ANG gene in 
the brain of the spontaneously hypertensive rat (SHR) as 
compared with the Wistar-Kyoto rat [14], and hypertension 
is significantly reduced by the intracerebroventricular injection 
with the synthetic antisense oligodeoxynucleotides of ANG 
mRNA to normotensive levels in SHR [15]. Furthermore, 
ANG mRNA levels were developmentally regulated in the 
rat brain, where its major production sites are glial cells 
[16-18], as a transient peak of its expression is the embryonic 
day 17 [19]. However, little is known about the regulatory 
mechanism of the human ANG promoter activity in the brain 
because of the limited availability of human materials. In the 
present study, we identified the potential DNA elements of the 
human ANG promoter functioning in a human glioblastoma 
cell line (A172) which endogenously expresses ANG mRNA 
[20] by in vitro transfection analyses. 
2. Materials and methods 
2.1. Plasmid constructions 
A promoter-less plasmid, SVOEcat was constructed by inserting the 
SV40 enhancer to the unique Bamftl site of pUCSVOcat [21]. The 
human ANG promoter-chloramphenicol acetyltransferase (CAT) chi-
meric constructs were made as follows: 13cat, DM4cat, DM7cat, 
DM7.8cat, DM8cat, DM9cat, DMIOcat, DM10.5cat, DM 11 cat, 
DM12cat contained 1266 bp (-1222 to +44), 791 bp (-747 to 
+44), 560 bp (-516 to +44), 388 bp (-344 to +44), 356 bp (-312 
to +44), 287 bp (-243 to +44), 150 bp (-106 to +44), 118 bp (-74 to 
+44), 103 bp (-59 to +44), and 76 bp (-32 to +44) fragments, 
respectively, and these DNA fragments were subcloned into the 
BglWHindlH sites of SVOEcat. DMIOcat was used as a template to 
construct internal deletion of ALE and mutations in 5'-AGCE2, 
AGCE1, and AGCE2 by oligonucleotides-directed mutagenesis [22]. 
After the internal deletion and the site-directed mutations were ob-
tained and confirmed by sequencing, the altered 140-bp or 150-bp 
fragments were subcloned into the BgftVHindUl sites of SVOEcat 
for A172 or SVOcat for HepG2 cells. 
2.2. Cell culture and transient expression assays 
A172 and HepG2 cell lines were maintained as described previously 
[20]. The cells were plated at a density of 1 X 106 cells/60-mm dish and 
transfected 24 h later by calcium phosphate co-precipitation [23] using 
6 ug plasmid DNA. After 48 h of culture, cell extracts were prepared 
and protein concentration was determined by the Bio-Rad protein 
assay kit. Extracts containing equal amounts of 40 |j.g of protein 
were used in CAT assays. The extent of conversion of chlorampheni-
col to its acetylated form was measured with a Bio-imaging analyzer 
(Model BAS2000; Fujix, Tokyo, Japan). All experiments were inde-
pendently performed at least six times for each construct. 
2.3. Preparation of nuclear extracts 
Nuclear extracts from A172 cells were prepared using the protocol 
of Dignam et al. [24]. The final protein concentration was about 
5 ug/ul. 
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2.4. Electrophoretic mobility shift assays (EMSA) 
EMSAs were performed as described previously [25]. 
3. Results 
3.1. Identification of the minimal region sufficient for promoter 
activity in human ANG-producing glioblastoma cells 
To identify potential elements that contribute to the human 
ANG gene expression in the brain, we analyzed its promoter 
coupled to the CAT gene in transiently transfected A172 cells. 
This was considered to be suitable model for our purpose, 
since it was a human glioblastoma cell line which endoge-
nously expressed the ANG mRNA [20]. The 1.3-kbp pro-
moter region functioned in A172 cells (Fig. 1). Deletion of 
the sequences from —1222 bp to —107 bp did not essentially 
affect the promoter activity; however, there was a drastic 
reduction in CAT activity when the upstream sequence was 
eliminated further up to —74 bp. These results suggested that 
the proximal promoter region from —106 bp to +44 bp was 
sufficient for the human ANG promoter activity in A172 cells. 
3.2. The human ANG promoter contains multiple binding sites 
for sequence-specific nuclear factors 
To investigate the binding activities of nuclear factors to the 
human ANG promoter, EMSA was performed using the dis-
sected DNA fragments that cover with the proximal promoter 
region, as the probes. First, we analyzed the core promoter 
region surrounding the transcription start point (Fig. 2). In-
cubation of AGCE1 (human ANG core promoter element 1) 
fragment with the nuclear extracts prepared from A172 cells 
produced the previously reported complex, AGCF1 (AGCE1-
binding factor J_), which was ubiquitously expressed [25] 
(data not shown). Incubation of B fragment with A172 
nuclear extracts produced retarded complexes which repre-
sented a sequence-specific interaction between each frag-
ment and nuclear factors, since the formation of these 
complexes was specifically reduced with molar excess of 
unlabeled competitors (Fig. 2B, lanes 1 to 4). On the con-
trary, incubation of C fragment with the nuclear extracts 
produced no specific complex (data not shown). To deter-
mine the subregion responsible for nuclear factor binding 
within B fragment, EMSA was conducted using A172 
nuclear extracts with the end-labeled B fragment, 200-fold 
molar excess of unlabeled D, E, and AGCE2 fragments. 
Only AGCE2 fragment could dissociate the specific com-
plexes (Fig. 2B, lanes 5 to 9). Moreover, double-stranded 
oligonucleotides containing the consensus binding sequences 
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Fig. 1. 5'-Deletion analysis of the human angiotensinogen promoter. Left: 5'-deletion constructs of the human ANG promoter-CAT hybrid 
genes. Thick horizontal lines and open boxes marked by CAT represent the promoter sequences and CAT vector sequences, respectively. 
Names of the constructs used are listed to the right. Right: A172 cells were transfected with 6 ug of the indicated CAT vector. After 48 h of 
culture, extracts containing equal amounts of 40 iig of protein were used in CAT assays. The CAT activities are presented relative to that of 
the 13cat construct (hatched columns). Thin lines represent the S.E.; « = 8 to 10. 











































Fig. 2. Identification of specific binding nuclear factors using different portions of the core promoter sequences. (A) On the top, near the core 
promoter region of human ANG gene is represented. Below, the ohgonucleotides used to detect specific interactions between the core promoter 
sequences and nuclear factors are indicated by thick horizontal lines. (B) EMSA. The indicated double-stranded ohgonucleotides were end-
labeled with T4 polynucleotide kinase using [y-32P]ATP. Five |xg of A172 nuclear extract (N.E.) were incubated with 0.5 ng of 32P-labeled 
probe. In a competition assay, 200-fold molar excess of the unlabeled ohgonucleotides, as indicated for each lane, were added to the reaction 
mixture. Binding reactions were resolved by 4.5% acrylamide, IXTBE electrophoresis. A specific nuclear factor, AGCF2, is indicated. The 
others are non-specific nuclear factors. 
failed to compete with AGCF-2-binding activities (data not 
shown). 
We next performed competition assays to examine the ef-
fects of the mutation in AGCE2 on the nuclear factor binding 
activities (Fig. 3). The DNA-protein complexes formed by 
AGCF2 binding to AGCE2 could be inhibited by molar ex-
cess of non-labeled AGCE2, but AGCE2m only partially re-
placed this binding (Fig. 3B, lanes 1 to 4). Furthermore, we 
analyzed the upstream region which contained ATF-like ele-
ment (ALE) and AGCE2-like sequences (Fig. 4A). Incubation 
of ALE fragment with the nuclear extracts produced several 
retarded complexes including CREB/ATF family and novel 
ones (manuscript in preparation). Incubation of CT+P frag-
ment produced no specific complex (data not shown). Finally, 
Fig. 3. Effect of AGCE2 mutation on the binding activities. (A) Oh-
gonucleotides comprising wild type (AGCE2) and mutant (AG-
CE2m) are shown. The positions of base substitutions are under-
lined. The mutations are indicated by boxed nucleotides. Double-
stranded versions of the indicated sequences were used in competi-
tion experiments. (B) EMSA was performed as described in the 
legend to Fig. 2B. In a competition assay, 200-fold molar excess of 
unlabeled ohgonucleotides, as indicated for each lane, were added 
to the reaction mixture. Binding reactions were resolved by 4.5% 
acrylamide, 1X TBE electrophoresis. A specific nuclear factor, 
AGCF2, is indicated. The others are non-specific nuclear factors. 
N.E., nuclear extract. 
incubation of 5'-AGCE2 fragment with the nuclear extracts 
produced low mobility complexes as observed in AGCE2 
fragment, and these complexes had the same sequence specif-
icity as AGCF2 (Fig. 4B). These results suggest that AGCF2 
binds to both 5'-AGCE2 and AGCE2. 
♦11 +26 
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Fig. 4. Identification of specific binding nuclear factors using different portions of the upstream promoter sequences. (A) On the top, the up-
stream promoter sequences of hAG gene, ATF-like motif and AGCE2-like motif are represented. Below, the ohgonucleotides used to detect 
specific interactions between the upstream promoter sequences and nuclear factors are indicated by thick horizontal lines. (B) EMSA was per-
formed as described in the legend to Fig. 2B. In a competition assay, 200-fold molar excess of unlabeled ohgonucleotides, as indicated for each 
lane, were added to the reaction mixture. Binding reactions were resolved by 4.5% acrylamide, 1XTBE electrophoresis. A specific nuclear fac-
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Fig. 5. Effects of mutations within ALE, 5'-AGCE2, AGCE1, and AGCE2 on the native promoter activities. Thick horizontal lines represent 
wild-type promoter sequences, open boxes marked CAT represent CAT vector sequences, unmarked open boxes represent TATA box, white 
vertical lines represent mutations (5'-AGCE2m, AGCElm, and AGCE2m), and hatched line represents internal deletion whose positions are in-
dicated below the line. Names of the constructs are listed to the right. Right, A172 were transfected with the indicated CAT vectors, and CAT 
assays were performed as described in Fig. 1. The CAT activities are presented relative to that of the DMIOcat construct (hatched columns). 
Thin lines represent the S.E.; « = 8 to 10. 
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3.3. ALE, 5'-AGCE2, AGCEl, and AGCE2 function as critical 
components of the human ANG promoter 
We previously reported that the proximal promoter region 
from —106 to +44 was important for the human A N G tran-
scription in human hepatoma cell line (HepG2) [21]. Further-
more, A G C F 1 - , ALF- , and AGCF2-binding activities were 
also observed in HepG2 cells (data not shown and [25]). To 
assess the role of A L F , A G C F 1 , and A G C F 2 for the human 
A N G constitutive transcription, the mutat ions that affect nu-
clear factor-binding activities (Figs. 3 and 4 and [25]) were 
introduced into the promoter, and then those C A T activities 
were analyzed in both A172 and HepG2 cells. In the case of 
A L F , the internal deletion of its binding site was used in order 
to avoid the generation of the other C R E B / A T F family bind-
ing sequences. As shown in Fig. 5, the deletion of A L E and 
the mutat ions within A G C E l decreased the transcription ac-
tivity in both HepG2 and A172 cells. Interestingly, the muta-
tions within 5 ' -AGCE2 and A G C E 2 decreased the transcrip-
tional activity in A172 cells but rather increased its activity in 
HepG2 cells. Taken together, these results suggested that 
ALE, 5 ' -AGCE2, A G C E l , and A G C E 2 were essential for 
the efficient human A N G promoter activity in A172 cells, 
and AGCF2-binding sites differentially functioned in a cell 
type-dependent manner. 
4. Discussion 
The position of A G C E l which is located in the region be-
tween T A T A box and the transcription initiation site is very 
unique. Recently, we reported that A G C F 1 is an authentic 
regulator of human A N G transcription by mediating the re-
sponsiveness to upstream and downstream element-binding 
factors in HepG2 cells [25]. Although the human A N G down-
stream enhancer core elements could not work in A172 cells 
[26,27], A L E functions in both cell lines (Fig. 5). In A172 
cells, A G C E l may also mediate the responsiveness to ALE-, 
5 ' -AGCE2-, and AGCE2-binding factors. This would be sup-
ported by the observation that both A L F - and AGCF2-bind-
ing elements efficiently activated the human A N G promoter , 
but had very weak effects on the heterologous herpes simplex 
virus thymidine kinase promoter which had no AGCEl- l ike 
sequence in A172 cells (data not shown). 
Cell-specific cofactors have been identified and discovered 
to give a cell-type specific function to ubiquitously expressed 
sequence-specific transcription factors. Oct-binding factor 1 
(OBF-1) expressed only in B cells has no intrinsic DNA-bind-
ing activity and interacts with ubiquitously expressed Oct-1 on 
promoter D N A . It is suggested that OBF-1 can give a B cell-
specific activation function to Oct-1 [28]. Fur thermore, Krebs 
et al. [29] reported that papovavirus JC core promoter func-
tions in a glial cell-specific manner , and suggested the require-
ment of a glial cell-specific coactivator. We indicated the dif-
ferential action of AGCF2-binding elements upon the human 
A N G promoter activity between A172 and HepG2 cells, 
al though AGCF2-binding activities were detected in all the 
cell lines tested, regardless of whether human A N G is ex-
pressed or not (data not shown). These results provide the 
possibility that A G C F 2 may have an important function in 
the glia-dependent A N G expression through either the inter-
action of a cell-type specific cofactor or a specific modification 
or both. Further study will be necessary to define, by means 
of cloning the c D N A encoding A G C F 2 , the molecular mech-
anism by which they can maintain the promoter activity in the 
brain. 
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